Abstract

Public Health Relevance

The goals of this proposal are to develop and optimize compounds targeting apolipoprotein (apo) E4?induced GABAergic interneuron impairment as a novel therapeutic approach for Alzheimer?s disease and to test the efficacy of the lead GABAergic interneuron protectors in apoE4-knock-in mice and human induced pluripotent stem cell?derived neurons carrying the apoE4 allele.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44AG063691-03
Application #
10067503
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Martin, Zane
Project Start
2019-05-01
Project End
2021-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
3
Fiscal Year
2021
Total Cost
Indirect Cost

  Institution

Name
Gabaeron, Inc.
Department
Type
DUNS #
080971549
City
San Francisco
State
CA
Country
United States
Zip Code
94158